drugset / Trial / NCT03588936
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6 (IL-6) inhibition in participants with relapsed disease post-allogeneic transplant.
Timeline
- Start
- 2018-09-14
- Primary completion
- 2020-07-15
- Completion
- 2020-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 0.25 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |